Health · 16 views
Investigational EGFR x HER3 therapy supports Phase III dose after lung cancer trial
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5…
Summary
An investigational EGFR x HER3 antibody-drug conjugate demonstrated promising efficacy with a tolerable safety profile in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC), supporting selection of the 2.5 mg/kg dose for evaluation in the global Phase III IZABRIGHT-Lung01 registrational study. These results will be presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC) in Seoul, Republic of Korea.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- AACR's annual cancer progress report highlights promising advances for patientsContinue reading
- Brain MRI surveillance without prophylactic cranial irradiation improves cognitive outcomes in small cell lung cancerContinue reading
- New model tracks vocal fold fatigue as it develops, study showsContinue reading
- Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastasesContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow